Elevar Therapeutics

Asia
Pharma

Legend Biotech, Merck, Otsuka—Fierce Pharma Asia

Legend's CEO resigned. Merck deleted a trial plan to combine its PD-1xVEGF bispecific with its TROP2 ADC. Otsuka's novel ADHD med wins FDA nod.
Angus Liu Jul 31, 2026 9:00am
FDA

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Jul 28, 2026 3:02pm
Asia

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am
FDA stop sign

FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time

Jul 10, 2026 10:55am
Asia

AZ, Boehringer-Simcere, Daiichi and more—Fierce Pharma Asia

Jan 30, 2026 7:45am
newspaper

Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia

Aug 15, 2025 8:31am